WHITE BLOOD CELL MIGRATION STUDY
(In-111-WBCs, Tc-99m-HMPAO-WBCs)

Overview

• The White Blood Cell Migration Study demonstrates the distribution of labeled autologous white blood cells within the body at various times after intravenous injection. When labeled with technetium-99m, the study can be completed in several hours and is optimal for imaging inflammatory bowel disease. When labeled with indium-111, the study can be extended over two days and is preferred for the diagnosis of vertebral body osteomyelitis. White blood cells labeled with either radioisotope may be used for imaging osteomyelitis outside of the spine and soft tissue abscesses.

Indications

• Detection of abscesses and infection in soft tissues, particularly in patients without localizing findings (1-3).

• Diagnosis of infection in the skeleton (4-8).

• Evaluation of inflammatory bowel disease (9-11).

Examination Time

• Initially: 15 minutes for withdrawal of 50 mL of blood.

• At 1 hour: 15 minutes for injection of the radiopharmaceutical.

• Later:
  > In-111-WBCs: 1 hour for imaging at 6 and/or 24 hours (12). (Delayed images beyond the routine set of images may be needed.)
  > Tc-99m-HMPAO-WBCs: 1 hour for imaging at 2 hours (3,13).

Patient Preparation

• None (antibiotics do not appear to interfere) (3).

Equipment & Energy Windows

• Gamma camera: Large field of view, preferably with dual heads.

• Collimator:
  > In-111-WBCs: Medium energy, parallel hole.
  > Tc-99m-HMPAO-WBCs: Low energy, high resolution, parallel hole.
• Energy windows:
  > In-111-WBCs:
    θ One pulse height analyzer: 156 to 272 keV.
    θ Two pulse height analyzers: 20% windows centered at 171 and 245 keV.
  > Tc-99m-HMPAO-WBCs: 20% window centered at 140 keV.

Radiopharmaceutical, Dose, & Technique of Administration

• Radiopharmaceutical (1,3,13-15):
  > In-111-white blood cells - radiopharmaceutical of choice for infection of the spine, equal for infection of rest of skeleton and soft tissue infection.
  > Tc-99m-HMPAO-WBCs - radiopharmaceutical of choice for inflammatory bowel disease, equal for soft tissue infection (1,3,13).

• Dose:
  > In-111-WBCs: 500 µCi (18.5 MBq) (8).
  > Tc-99m-HMPAO-WBCs: 10-25 mCi (370 MBq) (3).

• Technique of administration: Standard intravenous injection.

Patient Position & Imaging Field

• Patient position: Supine.

• Imaging field: Usually entire torso; check with the nuclear medicine

Acquisition Protocol

• Initial imaging:
  > In-111-WBCs: 24 hours (occasionally 6 hours).
  > Tc-99m-HMPAO-WBCs: 2 hours for (3).

• ANT and POST images are acquired of the torso, and of the extremities as indicated; occasionally other projections are obtained.
  θ For moving acquisition: Use a camera/table motion of approximately 5-10 cm/min.
  θ Static acquisition protocol: Acquire images for approximately 5 minutes each.

• SPECT imaging - use routinely for limited studies and areas of uncertainty (16):
  1. Image acquisition parameters:
     a) degrees of rotation: 360°.
     b) number of images: 64.
     c) time per image: 20 seconds.
• Delayed imaging (may be needed to increase the certainty of diagnosis (1)):
  > In-111-WBCs: 48 hours.
  > Tc-99m-HMPAO-WBCs: 24 hours for Tc-99m-HMPAO-WBCs (16),

Protocol Summary Diagrams

![Diagram of In-111-WBCs]

<table>
<thead>
<tr>
<th>Action</th>
<th>Whole body images</th>
<th>Whole body images</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td>0</td>
<td>24 hr</td>
</tr>
</tbody>
</table>

![Diagram of Tc-99m-HMPAO-WBCs]

<table>
<thead>
<tr>
<th>Action</th>
<th>Whole body images</th>
<th>Whole body images</th>
</tr>
</thead>
<tbody>
<tr>
<td>Time</td>
<td>0</td>
<td>2 hr</td>
</tr>
</tbody>
</table>

Data Processing

• SPECT image reconstruction:
  1. The exact procedure for processing SPECT images depends on the computer software being used. This varies with the manufacturer and, in general, the manufacturer’s protocol should be followed.
  2. The reconstruction process in general terms is:
     a) correct the 64 planar images for uniformity (camera non-uniformity) using a high count, e.g. 30 million count, cobalt-57 flood acquisition.
     b) check the images for patient motion and apply a motion correction algorithm if indicated and if available.
     c) if the entire field of view is not of interest, indicate the region that is of interest so that computer time is not expended reconstructing tomograms outside the region of interest.
     d) specify the filters to be used in the reconstruction process and the pixel thickness of the tomogram (usually 1 or 2 pixels).
     e) reconstruct transverse, sagittal, and coronal image.

Optional Maneuvers

• Bone marrow imaging with Tc-99m-sulfur colloid: May be performed in conjunction with In-111-WBC studies for osteomyelitis to increase
Pethidine to reduce hepatobiliary excretion: When imaging inflammatory bowel disease with Tc-99m-HMPAO-WBCs, can give pethidine (an opiate) to constrict the sphincter of Oddi and reduce excretion of of Tc-99m-WBC by products (16).

Bone mineral imaging with Tc-99m-HMP or MDP: May be performed in conjunction with In-111-WBC studies for osteomyelitis to increase

**Principle Radiation Emission Data - In-111** (21)

- Physical half-life = 2.83 days.

<table>
<thead>
<tr>
<th>Radiation</th>
<th>Mean % per disintegration</th>
<th>Mean energy (keV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma-2</td>
<td>90.2</td>
<td>171.3</td>
</tr>
<tr>
<td>Gamma-3</td>
<td>94.0</td>
<td>245.3</td>
</tr>
</tbody>
</table>

**Dosimetry - In-111-White Blood Cells** (22,23)

<table>
<thead>
<tr>
<th>Organ</th>
<th>rads/500 µCi</th>
<th>mGy/18.5 MBq</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen</td>
<td>11.9</td>
<td>119.0</td>
</tr>
<tr>
<td>Liver</td>
<td>1.9</td>
<td>19.0</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.8</td>
<td>7.5</td>
</tr>
<tr>
<td>Marrow</td>
<td>0.3</td>
<td>3.3</td>
</tr>
<tr>
<td>Total body</td>
<td>0.2</td>
<td>2.0</td>
</tr>
<tr>
<td>Ovaries</td>
<td>0.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Testes</td>
<td>0.01</td>
<td>0.1</td>
</tr>
</tbody>
</table>

**Principle Radiation Emission Data - Tc-99m** (24)

- Physical half-life = 6.01 hours.

<table>
<thead>
<tr>
<th>Radiation</th>
<th>Mean % per disintegration</th>
<th>Mean energy (keV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gamma-2</td>
<td>89.07</td>
<td>140.5</td>
</tr>
</tbody>
</table>

**Dosimetry - Tc-99m-HMPAO-White Blood Cells** (25)

<table>
<thead>
<tr>
<th>Organ</th>
<th>rads/10 mCi</th>
<th>mGy/370 MBq</th>
</tr>
</thead>
<tbody>
<tr>
<td>Spleen</td>
<td>2.3</td>
<td>23.3</td>
</tr>
<tr>
<td>Liver</td>
<td>1.6</td>
<td>16.3</td>
</tr>
<tr>
<td>Kidneys</td>
<td>1.4</td>
<td>13.7</td>
</tr>
<tr>
<td>Bladder wall</td>
<td>0.6</td>
<td>6.3</td>
</tr>
<tr>
<td>Lungs</td>
<td>0.4</td>
<td>3.7</td>
</tr>
<tr>
<td>Marrow</td>
<td>0.1</td>
<td>1.5</td>
</tr>
<tr>
<td>Total body</td>
<td>0.1</td>
<td>1.5</td>
</tr>
<tr>
<td>Ovaries</td>
<td>0.1</td>
<td>0.7</td>
</tr>
<tr>
<td>Testes</td>
<td>0.04</td>
<td>0.4</td>
</tr>
</tbody>
</table>
References


**Normal Findings**

